Upstream Bio (UPB) Other Gross PP&E Adjustments (2023 - 2026)
Upstream Bio's quarterly Other Gross PP&E Adjustments came in at -$1.4 million in Q1 2026, up 24.47% year-on-year from -$1.1 million in Q1 2025, and down 32.81% quarter-over-quarter from -$1.1 million in Q4 2025.
Upstream Bio has reported Other Gross PP&E Adjustments for 4 years, with the latest figure at -$1.4 million in Q1 2026.
- For the quarter ending Q1 2026, Other Gross PP&E Adjustments rose 24.47% year-over-year to -$1.4 million; the trailing twelve-month figure through Mar 2026 stood at -$1.4 million (up 24.47% YoY), and the FY2025 full-year result was -$1.1 million, up 29.81% from the prior year.
- Other Gross PP&E Adjustments for Q1 2026 stood at -$1.4 million, down from -$1.1 million in the prior quarter.
- The five-year high for Other Gross PP&E Adjustments was -$692000.0 in Q4 2023, with the low at -$2.0 million in Q3 2024.
- Average Other Gross PP&E Adjustments over 4 years is -$1.4 million, with a median of -$1.5 million recorded in 2024.
- Year-over-year, Other Gross PP&E Adjustments slumped 121.53% in 2024 and soared 45.8% in 2025.
- Tracing UPB's Other Gross PP&E Adjustments over 4 years: stood at -$692000.0 in 2023, then slumped by 121.53% to -$1.5 million in 2024, then climbed by 29.81% to -$1.1 million in 2025, then slumped by 32.81% to -$1.4 million in 2026.
- The last three Other Gross PP&E Adjustments figures came in at -$1.4 million (Q1 2026), -$1.1 million (Q4 2025), and -$1.1 million (Q3 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Other Gross PP&E Adjustments (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 1,216,509.61 Bn | 1,216,509.61 Bn | - | -83,048.00 |
| 2 | Alterity Therapeutics | 764,224.41 Bn | 764,224.38 Bn | - | -60,691.22 |
| 3 | Legend Biotech | 2,716.00 Bn | 2,715.71 Bn | 242.10 Mn | -285.20 Mn |
| 4 | Nanobiotix | 2,248.83 Bn | 2,248.77 Bn | - | - |
| 5 | Akari Therapeutics | 1,951.18 Bn | 1,951.17 Bn | - | -892,000.00 |
| 6 | Vertex Pharmaceuticals | 113.69 Bn | 106.44 Bn | 2.59 Bn | -1.69 Bn |
| 7 | Evaxion A | 64.16 Bn | 64.14 Bn | - | - |
| 8 | Regeneron Pharmaceuticals | 63.94 Bn | 55.18 Bn | 3.31 Bn | - |
| 9 | Alnylam Pharmaceuticals | 40.13 Bn | 37.12 Bn | 959.66 Mn | -189.30 Mn |
| 10 | Upstream Bio | 454.22 Mn | 454.22 Mn | -3.94 Mn | -1.43 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -1.43 Mn |
| Mar 31, 2026 | -1.43 Mn |
| Dec 31, 2025 | -1.08 Mn |
| Dec 31, 2025 | -1.08 Mn |
| Sep 30, 2025 | -1.07 Mn |
| Sep 30, 2025 | -1.07 Mn |
| Jun 30, 2025 | -1.92 Mn |
| Jun 30, 2025 | -1.92 Mn |
| Mar 31, 2025 | -1.89 Mn |
| Mar 31, 2025 | -1.89 Mn |
| Dec 31, 2024 | -1.53 Mn |
| Dec 31, 2024 | -1.53 Mn |
| Sep 30, 2024 | -1.98 Mn |
| Sep 30, 2024 | -1.98 Mn |
| Dec 31, 2023 | -692,000.00 |
| Dec 31, 2023 | -692,000.00 |